[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fuSKLgWgGKkxXXi9gB_8ch91cMcGohlpwGc7ukREg_9M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":56,"rows":63},"Charles University, Czech Republic",[4],219,false,63,9,51570,6,191,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Atrial Fibrillation",15,{"name":18,"count":19},"Motor Activity",8,{"name":21,"count":22},"Multiple Sclerosis",7,{"name":24,"count":25},"Diabetes Mellitus, Type 1",5,{"name":27,"count":28},"Pelvic Organ Prolapse",4,{"name":30,"count":28},"Critical Illness",{"name":32,"count":28},"Rehabilitation",{"name":34,"count":28},"Atrial Fibrillation (AF)",[36,41,46,51],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03338387","Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia","2007-12-16","Acipimox",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06045429","Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation","2025-06","Oroxid®",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05303805","Topical Sevoflurane for Treatment of Chronic Leg Ulcers","2026-04-30","Sevoflurane",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07435402","Reduction of Muscle Catabolism Through Brain Activation in Burn Patients","2029-12-31","Isoflurane Inhalational Sedation",[57,58,59,60,61,62],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[64,90,108,131,149,173,197,239,267,292,317,342,375,393,411,429,447,472,499,517,541,569,587,611,636,662,680,702,733,759,785,812,830,857,875,901,919,946],{"intervention":45,"totalTrials":65,"cells":66},1,{"EARLY_PHASE1":67,"PHASE1":70,"PHASE2":72,"PHASE3":74,"PHASE4":76,"NA":88},{"trials":68,"activeCount":69},[],0,{"trials":71,"activeCount":69},[],{"trials":73,"activeCount":69},[],{"trials":75,"activeCount":69},[],{"trials":77,"activeCount":65,"soonestReadout":44},[78],{"nctId":42,"briefTitle":43,"status":79,"phases":80,"primaryCompletion":44,"completion":81,"start":82,"enrollment":83,"conditions":84,"interventions":86},"RECRUITING",[61],"2025-12","2024-05-01",160,[85],"VAP - Ventilator Associated Pneumonia",[45,87],"Chlorhexidine mouthwash",{"trials":89,"activeCount":69},[],{"intervention":87,"totalTrials":65,"cells":91},{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":100,"NA":106},{"trials":93,"activeCount":69},[],{"trials":95,"activeCount":69},[],{"trials":97,"activeCount":69},[],{"trials":99,"activeCount":69},[],{"trials":101,"activeCount":65,"soonestReadout":44},[102],{"nctId":42,"briefTitle":43,"status":79,"phases":103,"primaryCompletion":44,"completion":81,"start":82,"enrollment":83,"conditions":104,"interventions":105},[61],[85],[45,87],{"trials":107,"activeCount":69},[],{"intervention":50,"totalTrials":65,"cells":109},{"EARLY_PHASE1":110,"PHASE1":112,"PHASE2":114,"PHASE3":116,"PHASE4":118,"NA":129},{"trials":111,"activeCount":69},[],{"trials":113,"activeCount":69},[],{"trials":115,"activeCount":69},[],{"trials":117,"activeCount":69},[],{"trials":119,"activeCount":65,"soonestReadout":49},[120],{"nctId":47,"briefTitle":48,"status":79,"phases":121,"primaryCompletion":49,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},[61],"2027-01-31","2022-05-02",50,[126],"Leg Ulcer",[50,128],"Cyteal",{"trials":130,"activeCount":69},[],{"intervention":128,"totalTrials":65,"cells":132},{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":141,"NA":147},{"trials":134,"activeCount":69},[],{"trials":136,"activeCount":69},[],{"trials":138,"activeCount":69},[],{"trials":140,"activeCount":69},[],{"trials":142,"activeCount":65,"soonestReadout":49},[143],{"nctId":47,"briefTitle":48,"status":79,"phases":144,"primaryCompletion":49,"completion":122,"start":123,"enrollment":124,"conditions":145,"interventions":146},[61],[126],[50,128],{"trials":148,"activeCount":69},[],{"intervention":40,"totalTrials":65,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":167,"PHASE4":169,"NA":171},{"trials":152,"activeCount":69},[],{"trials":154,"activeCount":69},[],{"trials":156,"activeCount":65,"soonestReadout":39},[157],{"nctId":37,"briefTitle":38,"status":158,"phases":159,"primaryCompletion":39,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":166},"ENROLLING_BY_INVITATION",[59],"2026-12-20","2003-05-06",24,[164,165],"Eating Disorder","Bulimia Nervosa",[40],{"trials":168,"activeCount":69},[],{"trials":170,"activeCount":69},[],{"trials":172,"activeCount":69},[],{"intervention":55,"totalTrials":65,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":185},{"trials":176,"activeCount":69},[],{"trials":178,"activeCount":69},[],{"trials":180,"activeCount":69},[],{"trials":182,"activeCount":69},[],{"trials":184,"activeCount":69},[],{"trials":186,"activeCount":65,"soonestReadout":54},[187],{"nctId":52,"briefTitle":53,"status":188,"phases":189,"primaryCompletion":54,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":196},"NOT_YET_RECRUITING",[62],"2030-06-30","2026-05-01",30,[194,30,195],"Burns - Multiple","Muscle Weakness",[55],{"intervention":198,"totalTrials":199,"cells":200},"Exenatide",2,{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":222,"NA":237},{"trials":202,"activeCount":69},[],{"trials":204,"activeCount":69},[],{"trials":206,"activeCount":69},[],{"trials":208,"activeCount":69},[209],{"nctId":210,"briefTitle":211,"status":212,"phases":213,"primaryCompletion":214,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":221},"NCT01373216","Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass","COMPLETED",[60],"2014-05","2014-12","2011-06",38,[219,220],"Coronary Artery Disease","Decreased Left Ventricular Function",[198],{"trials":223,"activeCount":69},[224],{"nctId":225,"briefTitle":226,"status":212,"phases":227,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":234},"NCT02092597","Safety Evaluation of Adverse Reactions in Diabetes",[61],"2015-10","2016-09","2013-10",42,[233],"Type 2 Diabetes Mellitus",[198,235,236],"Linagliptin","Gliclazide",{"trials":238,"activeCount":69},[],{"intervention":240,"totalTrials":65,"cells":241},"Atorvastatin, Amlodipine, Perindopril",{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":265},{"trials":243,"activeCount":69},[],{"trials":245,"activeCount":69},[],{"trials":247,"activeCount":69},[],{"trials":249,"activeCount":69},[],{"trials":251,"activeCount":69},[252],{"nctId":253,"briefTitle":254,"status":255,"phases":256,"primaryCompletion":257,"completion":257,"start":258,"enrollment":69,"conditions":259,"interventions":264},"NCT03047538","Fixed Combination for Lipid and Blood Pressure Control","WITHDRAWN",[61],"2019-12-31","2017-09-01",[260,261,262,263],"Arterial Hypertension","Dyslipidemias","Blood Pressure","Lipid Metabolism Disorders",[240],{"trials":266,"activeCount":69},[],{"intervention":268,"totalTrials":65,"cells":269},"Abciximab",{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":278,"NA":290},{"trials":271,"activeCount":69},[],{"trials":273,"activeCount":69},[],{"trials":275,"activeCount":69},[],{"trials":277,"activeCount":69},[],{"trials":279,"activeCount":69},[280],{"nctId":281,"briefTitle":282,"status":212,"phases":283,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":289},"NCT00420030","Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock",[61],"2009-06","2006-09",80,[288],"Shock, Cardiogenic",[268],{"trials":291,"activeCount":69},[],{"intervention":293,"totalTrials":65,"cells":294},"Midazolam",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":303,"NA":315},{"trials":296,"activeCount":69},[],{"trials":298,"activeCount":69},[],{"trials":300,"activeCount":69},[],{"trials":302,"activeCount":69},[],{"trials":304,"activeCount":69},[305],{"nctId":306,"briefTitle":307,"status":212,"phases":308,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},"NCT03791424","Changes of Skin Resistance After Midazolam and After the End of Anaesthesia",[61],"2015-06-26","2014-10-01",28,[313],"Anesthesia",[293],{"trials":316,"activeCount":69},[],{"intervention":318,"totalTrials":65,"cells":319},"Celecoxib 100 mg",{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":326,"PHASE4":328,"NA":340},{"trials":321,"activeCount":69},[],{"trials":323,"activeCount":69},[],{"trials":325,"activeCount":69},[],{"trials":327,"activeCount":69},[],{"trials":329,"activeCount":69},[330],{"nctId":331,"briefTitle":332,"status":212,"phases":333,"primaryCompletion":334,"completion":335,"start":336,"enrollment":231,"conditions":337,"interventions":339},"NCT05288374","Celecoxib in Postoperative Analgesia for Radius Fracture Surgery",[61],"2023-11-30","2023-12-31","2022-02-10",[338],"Pain, Postoperative",[318],{"trials":341,"activeCount":69},[],{"intervention":343,"totalTrials":65,"cells":344},"Morphine intrathecal",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":373},{"trials":346,"activeCount":69},[],{"trials":348,"activeCount":69},[],{"trials":350,"activeCount":69},[],{"trials":352,"activeCount":69},[],{"trials":354,"activeCount":69},[355],{"nctId":356,"briefTitle":357,"status":212,"phases":358,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":370},"NCT03007121","Intrathecal Morphine Analgesia vs. Continuous Epidural Analgesia vs. Systemic Analgesia in Colorectal Surgery.",[61],"2018-12-14","2018-12-17","2017-04-10",75,[364,365,366,367,368,369],"Analgesia, Patient-Controlled","Epidural Analgesia","Anesthesia; Spinal","Morphine","Surgery, Colorectal","Intravenous Drug Delivery Systems",[343,371,372],"Bupivacaine + Sufentanil epidural","Morphine intravenous",{"trials":374,"activeCount":69},[],{"intervention":371,"totalTrials":65,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":391},{"trials":378,"activeCount":69},[],{"trials":380,"activeCount":69},[],{"trials":382,"activeCount":69},[],{"trials":384,"activeCount":69},[],{"trials":386,"activeCount":69},[387],{"nctId":356,"briefTitle":357,"status":212,"phases":388,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":389,"interventions":390},[61],[364,365,366,367,368,369],[343,371,372],{"trials":392,"activeCount":69},[],{"intervention":372,"totalTrials":65,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":409},{"trials":396,"activeCount":69},[],{"trials":398,"activeCount":69},[],{"trials":400,"activeCount":69},[],{"trials":402,"activeCount":69},[],{"trials":404,"activeCount":69},[405],{"nctId":356,"briefTitle":357,"status":212,"phases":406,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":407,"interventions":408},[61],[364,365,366,367,368,369],[343,371,372],{"trials":410,"activeCount":69},[],{"intervention":235,"totalTrials":65,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":419,"PHASE4":421,"NA":427},{"trials":414,"activeCount":69},[],{"trials":416,"activeCount":69},[],{"trials":418,"activeCount":69},[],{"trials":420,"activeCount":69},[],{"trials":422,"activeCount":69},[423],{"nctId":225,"briefTitle":226,"status":212,"phases":424,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":425,"interventions":426},[61],[233],[198,235,236],{"trials":428,"activeCount":69},[],{"intervention":236,"totalTrials":65,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":437,"PHASE4":439,"NA":445},{"trials":432,"activeCount":69},[],{"trials":434,"activeCount":69},[],{"trials":436,"activeCount":69},[],{"trials":438,"activeCount":69},[],{"trials":440,"activeCount":69},[441],{"nctId":225,"briefTitle":226,"status":212,"phases":442,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":443,"interventions":444},[61],[233],[198,235,236],{"trials":446,"activeCount":69},[],{"intervention":448,"totalTrials":65,"cells":449},"Synacthen infusion during adrenal venous sampling",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":470},{"trials":451,"activeCount":69},[],{"trials":453,"activeCount":69},[],{"trials":455,"activeCount":69},[],{"trials":457,"activeCount":69},[],{"trials":459,"activeCount":69},[460],{"nctId":461,"briefTitle":462,"status":463,"phases":464,"primaryCompletion":215,"completion":215,"start":465,"enrollment":466,"conditions":467,"interventions":469},"NCT02127840","Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism","UNKNOWN",[61],"2011-03",40,[468],"Primary Aldosteronism",[448],{"trials":471,"activeCount":69},[],{"intervention":473,"totalTrials":65,"cells":474},"Rocuronium",{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":497},{"trials":476,"activeCount":69},[],{"trials":478,"activeCount":69},[],{"trials":480,"activeCount":69},[],{"trials":482,"activeCount":69},[],{"trials":484,"activeCount":69},[485],{"nctId":486,"briefTitle":487,"status":212,"phases":488,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":495},"NCT01941628","Comparison of Surgical Conditions in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine",[61],"2016-12-30","2018-04-03","2014-08-16",91,[494],"Cesarean Section",[473,496],"Succinylcholine",{"trials":498,"activeCount":69},[],{"intervention":496,"totalTrials":65,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":515},{"trials":502,"activeCount":69},[],{"trials":504,"activeCount":69},[],{"trials":506,"activeCount":69},[],{"trials":508,"activeCount":69},[],{"trials":510,"activeCount":69},[511],{"nctId":486,"briefTitle":487,"status":212,"phases":512,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":513,"interventions":514},[61],[494],[473,496],{"trials":516,"activeCount":69},[],{"intervention":518,"totalTrials":65,"cells":519},"NOAC",{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":528,"NA":539},{"trials":521,"activeCount":69},[],{"trials":523,"activeCount":69},[],{"trials":525,"activeCount":69},[],{"trials":527,"activeCount":69},[],{"trials":529,"activeCount":69},[530],{"nctId":531,"briefTitle":532,"status":212,"phases":533,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":538},"NCT02426944","Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation",[61],"2019-07-20","2015-10-13",400,[15],[518],{"trials":540,"activeCount":69},[],{"intervention":542,"totalTrials":65,"cells":543},"Propafenone i.v.",{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":552,"NA":567},{"trials":545,"activeCount":69},[],{"trials":547,"activeCount":69},[],{"trials":549,"activeCount":69},[],{"trials":551,"activeCount":69},[],{"trials":553,"activeCount":69},[554],{"nctId":555,"briefTitle":556,"status":212,"phases":557,"primaryCompletion":558,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":565},"NCT03029169","Propafenone Versus Amiodarone in Septic Shock",[61],"2022-07-04","2022-08-01","2017-10-23",210,[563,564],"Supraventricular Arrhythmia","Septic Shock",[542,566],"Amiodarone i.v.",{"trials":568,"activeCount":69},[],{"intervention":566,"totalTrials":65,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":585},{"trials":572,"activeCount":69},[],{"trials":574,"activeCount":69},[],{"trials":576,"activeCount":69},[],{"trials":578,"activeCount":69},[],{"trials":580,"activeCount":69},[581],{"nctId":555,"briefTitle":556,"status":212,"phases":582,"primaryCompletion":558,"completion":559,"start":560,"enrollment":561,"conditions":583,"interventions":584},[61],[563,564],[542,566],{"trials":586,"activeCount":69},[],{"intervention":367,"totalTrials":65,"cells":588},{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":595,"PHASE4":597,"NA":609},{"trials":590,"activeCount":69},[],{"trials":592,"activeCount":69},[],{"trials":594,"activeCount":69},[],{"trials":596,"activeCount":69},[],{"trials":598,"activeCount":69},[599],{"nctId":600,"briefTitle":601,"status":212,"phases":602,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":608},"NCT03675646","Spinal Morphine for Postoperative Analgesia in Urology",[61],"2017-06-30","2017-07-10","2016-03-05",98,[338],[367],{"trials":610,"activeCount":69},[],{"intervention":612,"totalTrials":65,"cells":613},"Risk Factor Modification",{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":632,"NA":634},{"trials":615,"activeCount":69},[],{"trials":617,"activeCount":69},[],{"trials":619,"activeCount":69},[],{"trials":621,"activeCount":69},[622],{"nctId":623,"briefTitle":624,"status":463,"phases":625,"primaryCompletion":626,"completion":627,"start":628,"enrollment":629,"conditions":630,"interventions":631},"NCT04011800","PRAGUE-25 Trial. Catheter Ablation vs. AADs and Risk Factor Modification.",[60],"2025-06-30","2025-12-30","2021-05-01",212,[15],[612],{"trials":633,"activeCount":69},[],{"trials":635,"activeCount":69},[],{"intervention":637,"totalTrials":65,"cells":638},"Remimazolam",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":658,"NA":660},{"trials":640,"activeCount":69},[],{"trials":642,"activeCount":69},[],{"trials":644,"activeCount":69},[],{"trials":646,"activeCount":69},[647],{"nctId":648,"briefTitle":649,"status":212,"phases":650,"primaryCompletion":651,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":656},"NCT06013345","COnventional Vs. Optimised PERiprocedural Analgosedation Vs. Total IntraVEnous Anaesthesia for Pulsed-Field Ablation (COOPERATIVE-PFA)",[60],"2024-09-30","2024-12-01","2023-10-25",127,[15],[637,657,657],"Propofol",{"trials":659,"activeCount":69},[],{"trials":661,"activeCount":69},[],{"intervention":657,"totalTrials":65,"cells":663},{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":676,"NA":678},{"trials":665,"activeCount":69},[],{"trials":667,"activeCount":69},[],{"trials":669,"activeCount":69},[],{"trials":671,"activeCount":69},[672],{"nctId":648,"briefTitle":649,"status":212,"phases":673,"primaryCompletion":651,"completion":652,"start":653,"enrollment":654,"conditions":674,"interventions":675},[60],[15],[637,657,657],{"trials":677,"activeCount":69},[],{"trials":679,"activeCount":69},[],{"intervention":681,"totalTrials":65,"cells":682},"candesartan",{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":684,"activeCount":69},[],{"trials":686,"activeCount":69},[],{"trials":688,"activeCount":69},[689],{"nctId":690,"briefTitle":691,"status":463,"phases":692,"conditions":693,"interventions":695},"NCT00430833","CHANCE - Candesartan in Hypertrophic Cardiomyopathy",[59],[694],"Hypertrophic Cardiomyopathy",[681],{"trials":697,"activeCount":69},[],{"trials":699,"activeCount":69},[],{"trials":701,"activeCount":69},[],{"intervention":703,"totalTrials":199,"cells":704},"clopidogrel",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":722,"NA":724},{"trials":706,"activeCount":69},[],{"trials":708,"activeCount":69},[],{"trials":710,"activeCount":69},[],{"trials":712,"activeCount":69},[713],{"nctId":714,"briefTitle":715,"status":212,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"conditions":719,"interventions":721},"NCT00432120","Clopidogrel Only Before Percutaneous Coronary Intervention or Before Every Coronarography?",[60],"2007-07","2006-03",[720],"Ischemic Heart Disease",[703],{"trials":723,"activeCount":69},[],{"trials":725,"activeCount":69},[726],{"nctId":727,"briefTitle":728,"status":729,"phases":730,"conditions":731,"interventions":732},"NCT00839345","Clopidogrel Resistance and the Possibility of Its Affection","TEMPORARILY_NOT_AVAILABLE",[],[219],[703],{"intervention":734,"totalTrials":65,"cells":735},"vaccination against human papillomavirus infection",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":737,"activeCount":69},[],{"trials":739,"activeCount":69},[],{"trials":741,"activeCount":69},[],{"trials":743,"activeCount":69},[],{"trials":745,"activeCount":69},[],{"trials":747,"activeCount":69},[748],{"nctId":749,"briefTitle":750,"status":212,"phases":751,"primaryCompletion":752,"completion":753,"start":82,"enrollment":754,"conditions":755,"interventions":758},"NCT06258564","The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization",[],"2024-12-31","2025-01-30",12000,[756,757],"Cervical Intraepithelial Neoplasia Grade 2\u002F3","Recurrence",[734],{"intervention":760,"totalTrials":65,"cells":761},"PCR and sequencing",{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":768,"PHASE4":770,"NA":772},{"trials":763,"activeCount":69},[],{"trials":765,"activeCount":69},[],{"trials":767,"activeCount":69},[],{"trials":769,"activeCount":69},[],{"trials":771,"activeCount":69},[],{"trials":773,"activeCount":69},[774],{"nctId":775,"briefTitle":776,"status":463,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT03090763","Role of Circulating MicroRNAs in Pathogenesis of Aneurysms of the Abdominal and Thoracic Aorta - Study \"Micro AAA\"",[],"2018-05-01","2019-06-01","2016-11-01",200,[783],"Aortic Aneurysm",[760],{"intervention":786,"totalTrials":65,"cells":787},"Metformin",{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":798},{"trials":789,"activeCount":69},[],{"trials":791,"activeCount":69},[],{"trials":793,"activeCount":69},[],{"trials":795,"activeCount":69},[],{"trials":797,"activeCount":69},[],{"trials":799,"activeCount":69},[800],{"nctId":801,"briefTitle":802,"status":212,"phases":803,"primaryCompletion":804,"completion":805,"start":806,"enrollment":807,"conditions":808,"interventions":810},"NCT03189732","Effect of Metformin on Exercise-induced Lipolysis",[62],"2017-08-30","2018-01","2015-10-01",10,[809],"Diabetes Mellitus, Type 2",[786,811],"Metformin local in AT",{"intervention":811,"totalTrials":65,"cells":813},{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":822,"NA":824},{"trials":815,"activeCount":69},[],{"trials":817,"activeCount":69},[],{"trials":819,"activeCount":69},[],{"trials":821,"activeCount":69},[],{"trials":823,"activeCount":69},[],{"trials":825,"activeCount":69},[826],{"nctId":801,"briefTitle":802,"status":212,"phases":827,"primaryCompletion":804,"completion":805,"start":806,"enrollment":807,"conditions":828,"interventions":829},[62],[809],[786,811],{"intervention":831,"totalTrials":65,"cells":832},"pegylated interferon",{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":841,"NA":843},{"trials":834,"activeCount":69},[],{"trials":836,"activeCount":69},[],{"trials":838,"activeCount":69},[],{"trials":840,"activeCount":69},[],{"trials":842,"activeCount":69},[],{"trials":844,"activeCount":69},[845],{"nctId":846,"briefTitle":847,"status":463,"phases":848,"primaryCompletion":284,"completion":849,"start":850,"enrollment":851,"conditions":852,"interventions":855},"NCT00842205","Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection",[62],"2009-12","2007-01",150,[853,854],"Chronic HCV Infection","Nonalcoholic Steatohepatitis",[831,856],"Ribavarin",{"intervention":856,"totalTrials":65,"cells":858},{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":860,"activeCount":69},[],{"trials":862,"activeCount":69},[],{"trials":864,"activeCount":69},[],{"trials":866,"activeCount":69},[],{"trials":868,"activeCount":69},[],{"trials":870,"activeCount":69},[871],{"nctId":846,"briefTitle":847,"status":463,"phases":872,"primaryCompletion":284,"completion":849,"start":850,"enrollment":851,"conditions":873,"interventions":874},[62],[853,854],[831,856],{"intervention":876,"totalTrials":65,"cells":877},"Sedation using only Propofol.",{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":879,"activeCount":69},[],{"trials":881,"activeCount":69},[],{"trials":883,"activeCount":69},[],{"trials":885,"activeCount":69},[],{"trials":887,"activeCount":69},[],{"trials":889,"activeCount":69},[890],{"nctId":891,"briefTitle":892,"status":212,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":124,"conditions":896,"interventions":899},"NCT06060626","Optimization of Sedation Protocol for Endoscopic Procedures Using Impedance Ventilation Monitor.",[62],"2025-01-22","2023-11-16",[897,898],"Sedation Complication","Ventilatory Depression",[876,900],"Sedation using combination of Propofol and Fentanyl.",{"intervention":900,"totalTrials":65,"cells":902},{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":904,"activeCount":69},[],{"trials":906,"activeCount":69},[],{"trials":908,"activeCount":69},[],{"trials":910,"activeCount":69},[],{"trials":912,"activeCount":69},[],{"trials":914,"activeCount":69},[915],{"nctId":891,"briefTitle":892,"status":212,"phases":916,"primaryCompletion":894,"completion":894,"start":895,"enrollment":124,"conditions":917,"interventions":918},[62],[897,898],[876,900],{"intervention":920,"totalTrials":65,"cells":921},"Remifentanil",{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":923,"activeCount":69},[],{"trials":925,"activeCount":69},[],{"trials":927,"activeCount":69},[],{"trials":929,"activeCount":69},[],{"trials":931,"activeCount":69},[],{"trials":933,"activeCount":69},[934],{"nctId":935,"briefTitle":936,"status":212,"phases":937,"primaryCompletion":938,"completion":939,"start":465,"enrollment":940,"conditions":941,"interventions":945},"NCT01550640","Pharmacogenetics of Remifentanil in Patients With Hypertension Undergoing Cesarean Delivery Under General Anesthesia",[62],"2014-04","2014-08",149,[942,943,944],"Pregnancy","Cesarean Delivery","General Anesthesia",[920],{"intervention":947,"totalTrials":65,"cells":948},"insulin",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":950,"activeCount":69},[],{"trials":952,"activeCount":69},[],{"trials":954,"activeCount":69},[],{"trials":956,"activeCount":69},[],{"trials":958,"activeCount":69},[],{"trials":960,"activeCount":69},[961],{"nctId":962,"briefTitle":963,"status":212,"phases":964,"primaryCompletion":965,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":970},"NCT00764712","Comparison of Three Protocols for Tight Glycemic Control in Cardiac Surgery Patients",[62],"2008-04","2008-02",120,[969],"Hyperglycemia",[947]]